| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TXNDC17 |
| Uniprot No | Q9BRA2 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-123aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSHMARYEE VSVSGFEEFH RAVEQHNGKT IFAYFTGSKD AGGKSWCPDC VQAEPVVREG LKHISEGCVFIYCQVGEKPY WKDPNNDFRK NLKVTAVPTL LKYGTPQKLV ESECLQANLV EMLFSED |
| 预测分子量 | 17 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于TXNDC17重组蛋白的假设性参考文献示例(仅供学术参考，实际文献请通过数据库查询)：
---
1. **文献名称**：*Recombinant TXNDC17 attenuates oxidative stress in hepatocellular carcinoma cells*
**作者**：Zhang L. et al. (2020)
**摘要**：研究报道了TXNDC17重组蛋白在大肠杆菌中的高效表达与纯化，并通过体外实验证实其通过调节硫氧还蛋白通路抑制肝癌细胞氧化应激，降低细胞凋亡率。
2. **文献名称**：*Structural characterization of human TXNDC17 and its role in protein folding*
**作者**：Lee S. et al. (2021)
**摘要**：通过X射线晶体学解析TXNDC17重组蛋白的三维结构，揭示其与底物结合的活性位点，并证明其在协助错误折叠蛋白修复中的分子机制。
3. **文献名称**：*TXNDC17 recombinant protein modulates ER stress in neurodegenerative models*
**作者**：Brown K. et al. (2022)
**摘要**：利用哺乳动物细胞表达系统制备TXNDC17重组蛋白，发现其通过缓解内质网应激，显著改善阿尔茨海默病模型中的神经元存活率。
---
**提示**：以上内容为示例，实际文献请通过PubMed、Web of Science或Google Scholar检索关键词“TXNDC17 recombinant protein”获取。
**Background of TXNDC17 Recombinant Protein**
TXNDC17 (Thioredoxin Domain-Containing Protein 17) is a member of the thioredoxin (Trx) protein family, characterized by a conserved thioredoxin-fold domain involved in redox regulation and cellular antioxidant defense. This protein is encoded by the *TXNDC17* gene, which is evolutionarily conserved across eukaryotes, underscoring its functional significance. TXNDC17 contains an N-terminal thioredoxin-like domain and a C-terminal region with variable sequences, suggesting roles beyond classical redox activity, potentially in protein-protein interactions or substrate recognition.
Recombinant TXNDC17 is engineered using expression systems (e.g., *E. coli* or mammalian cells) to produce purified, biologically active protein for research. Its recombinant form enables studies on molecular mechanisms, including oxidative stress response, apoptosis regulation, and cellular signaling pathways, such as MAPK/ERK. TXNDC17 has been implicated in diseases like cancer, where its dysregulation correlates with tumor progression, metastasis, and chemoresistance in hepatocellular carcinoma and breast cancer. It may act as a redox-sensitive chaperone or modulator of oncogenic signaling.
In metabolic disorders, TXNDC17 interacts with pathways influencing insulin sensitivity and lipid metabolism, highlighting its therapeutic potential. Recombinant TXNDC17 is also used to investigate its enzymatic activity, substrate specificity, and interactions with partners like peroxiredoxins or transcription factors. Despite progress, its exact physiological roles, tissue-specific expression patterns, and disease-related mechanisms remain incompletely understood, necessitating further functional and structural studies. Overall, TXNDC17 recombinant protein serves as a critical tool for exploring redox biology and developing targeted therapies for cancer and metabolic diseases.
×
